Foundayo (orforglipron): an explanation of the slimming pill with no specific dosage instructions

Short answer: Foundayo orforglipron is the first GLP-1 weight-loss pill based on a small molecule. Unlike other oral GLP-1 medicines, it can be taken at any time, with or without food or water. It is not yet available in the Netherlands.

Foundayo is the brand name for orforglipron, and this weight-loss pill differs in one key respect from all previous oral GLP-1 medicines. Whereas a tablet such as oral semaglutide must be taken on an empty stomach, Foundayo can be taken at any time of day without any restrictions regarding food or water. This is because orforglipron is not a peptide, but a small molecule – a difference we explain below. In this article, you can read exactly what Foundayo is, how it works, how effective it is, what side effects are associated with it, and when it is expected to become available in the Netherlands.

What is Foundayo?

Foundayo is the brand name for orforglipron, the first weight-loss medicine in tablet form that uses a small molecule rather than a peptide. The medicine was developed by Eli Lilly and was approved by the US FDA on 1 April 2026. This makes it the world’s first non-peptide-based GLP-1 receptor agonist using a small molecule to be brought to market.

The difference between a peptide and a small molecule is more than just a technical detail. Peptide medicines such as semaglutide are broken down in the stomach, which requires strict dosing guidelines to ensure that a sufficient amount of the active substance enters the body. Orforglipron is chemically structured in such a way that it remains stable in the gastrointestinal tract, and therefore these guidelines are largely no longer necessary.

How does Foundayo work?

Foundayo works by activating the GLP-1 receptor, just like the well-known injectable medicines. This activation slows down gastric emptying, curbs appetite and prolongs the feeling of fullness, so that you eat less without constantly feeling hungry. If you would like to know more about how the GLP-1 mechanism works, you will find a more detailed explanation there.

The difference compared with other GLP-1 medicines lies not in the mechanism of action, but in the chemical composition. A small molecule is more stable in the gastrointestinal tract than a peptide, and it is precisely this stability that makes it possible to take one tablet once a day without the need to fast. Research into the mechanism of action shows that orforglipron activates the receptor via a non-peptide pathway, which explains its stability in the body.

How effective is Foundayo?

Foundayo delivers clinically relevant weight loss comparable to that of injectable GLP-1 preparations. Phase 3 trials in obesity show that orforglipron, at the highest dose, led to weight loss of up to approximately nine kilograms, with a safety profile in line with that of the existing GLP-1 class. In people with early-stage type 2 diabetes, orforglipron reduced HbA1c by approximately 2.2 per cent, compared with approximately 1.4 per cent for Rybelsus.

Important to remember: this HbA1c result comes from diabetes research, as Rybelsus, the oral semaglutide tablet, is approved for type 2 diabetes, although, like Ozempic, it is also used off-label for weight loss. The final effect depends largely on consistent use in combination with lifestyle and dietary changes. There are no guarantees, and the figures are averages from studies. In a comparison with oral semaglutide for type 2 diabetes orforglipron performed at least as well in terms of blood sugar control.

What distinguishes Foundayo from the Wegovy tablet?

The main difference is the flexibility of administration: Foundayo can be taken at any time, whereas the Wegovy tablet, for example, must be taken on an empty stomach. Oral semaglutide must be taken with a little water on an empty stomach, followed by a waiting period of at least half an hour before eating or drinking anything. Foundayo does not have these restrictions, and furthermore, it contains a different active ingredient: orforglipron is a small molecule, whilst semaglutide is a peptide. The table below compares the three variants.

What are the side effects of Foundayo?

The side effects of Foundayo are similar to those seen across the entire GLP-1 class. These mainly include gastrointestinal symptoms such as nausea, diarrhoea, vomiting and constipation, which are usually mild and transient and occur particularly during the titration phase. This pattern is recognised from the well-known side effects of GLP-1 medicines, such as nausea. A recent review of new GLP-1 medicines describes this side-effect profile as consistent across the class.

The Pharmacotherapeutic Compass describes the same category of gastrointestinal symptoms for the GLP-1 class and, in rare cases, more serious problems such as pancreatitis or gallbladder problems. As Foundayo has only just been approved, long-term data are still limited. Always contact a doctor if you experience persistent or severe symptoms.

Is Foundayo already available in the Netherlands?

No, Foundayo is not yet available in the Netherlands. The medicine has been on the market in the US since 1 April 2026, but it has not yet been authorised in the Netherlands or the rest of the EU. The European assessment by the EMA is still ongoing, and it is not expected to become available in Europe until 2027.

This also means that there is as yet no clarity regarding the exact indication, any potential reimbursement, or the precise launch date for the Dutch market. If you’d like to get started right away, you can take a closer look at the weight-loss medication that is already available via a doctor. A doctor will assess whether such treatment is appropriate and safe for you.

Would you like to start taking weight-loss medication straight away? Goodweigh can help you get started

Foundayo looks promising, but is not yet available in the Netherlands. In the meantime, Goodweigh offers guidance on approved GLP-1 medication that is already available. A Dutch doctor will assess, via an online assessment, whether treatment is suitable for you and when you are eligible for GLP-1 medication. Would you like to know what the process involves? See how Goodweigh’s online assessment works.